(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are BIOTALYS, ZAPTEC, and SYNERGIE.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| BIOTALYS (BTLS.BR) | 4.84 | 15.51% | 2023-12-20 12:05:23 |
| ZAPTEC (ZAP.OL) | 20.26 | 14.27% | 2023-12-20 12:44:25 |
| SYNERGIE (SDG.PA) | 34.50 | 11.29% | 2023-12-20 13:23:27 |
| NEW SOURCES ENERGY (NSE.AS) | 0.04 | 10% | 2023-12-20 12:03:04 |
| NORTHERN OCEAN LTD (NOL.OL) | 10.78 | 8.89% | 2023-12-20 12:41:35 |
| DBV TECHNOLOGIES (DBV.PA) | 1.89 | 8.48% | 2023-12-20 13:02:06 |
| MAISONS DU MONDE (MDM.PA) | 5.55 | 8.08% | 2023-12-20 13:06:03 |
| ADOCIA (ADOC.PA) | 10.14 | 7.87% | 2023-12-20 12:44:49 |
| INNATE PHARMA (IPH.PA) | 2.65 | 7.72% | 2023-12-20 13:05:05 |
| ALAN ALLMAN (AAA.PA) | 9.90 | 6.45% | 2023-12-20 12:45:09 |
The three biggest losers today are ARGENX SE, CFI, and MCPHY ENERGY.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| ARGENX SE (ARGX.BR) | 317.00 | -23.63% | 2023-12-20 12:04:56 |
| CFI (CFI.PA) | 0.60 | -13.04% | 2023-12-20 13:01:05 |
| MCPHY ENERGY (MCPHY.PA) | 3.29 | -12.03% | 2023-12-20 13:20:09 |
| ADC SIIC (ALDV.PA) | 0.06 | -10.71% | 2023-12-20 12:44:48 |
| MOTA ENGIL (EGL.LS) | 3.71 | -9.29% | 2023-12-20 12:23:39 |
| PCI BIOTECH HOLD (PCIB.OL) | 2.01 | -8.45% | 2023-12-20 12:42:05 |
| OCEANTEAM (OTS.OL) | 1.28 | -8.27% | 2023-12-20 12:41:44 |
| EQVA (EQVA.OL) | 3.06 | -5.85% | 2023-12-20 12:26:04 |
| SOLSTAD OFFSHORE (SOFF.OL) | 39.02 | -5.75% | 2023-12-20 12:43:10 |
| PORCELEYNE FLES (PORF.AS) | 12.30 | -5.38% | 2023-12-20 12:03:31 |
Winners today
1. BIOTALYS (BTLS.BR)
15.51% Price Change
Biotalys NV, an agricultural technology company, discovers and develops novel biological products for the protection of food and crops. It primarily develops biofungicides, bioinsecticides, and biobactericides. The company was formerly known as Agrosavfe NV. Biotalys NV was incorporated in 2013 and is headquartered in Gent, Belgium.
BEL 20 ended the session with BIOTALYS jumping 15.51% to €4.84 on Wednesday while BEL 20 slid 2.4% to €3,652.82.
Earnings Per Share
As for profitability, BIOTALYS has a trailing twelve months EPS of €-0.76.
Volatility
BIOTALYS’s last week, last month’s, and last quarter’s current intraday variation average was 7.42%, 3.25%, and 5.69%.
BIOTALYS’s highest amplitude of average volatility was 8.36% (last week), 10.89% (last month), and 5.69% (last quarter).
More news about BIOTALYS.
2. ZAPTEC (ZAP.OL)
14.27% Price Change
Zaptec ASA engages in the development and sale of chargers, charging systems, and services for electric car charging in Norway, Sweden, Switzerland, Denmark, Iceland, rest of Europe, and internationally. It offers Zaptec Go, a charging unit for use in homes, private garages, or parking spaces; Zaptec Pro, a charging station for parking spaces in housing cooperatives and co-ownership properties, companies, and newbuilds; charging stations for outdoor installations; Zaptec Park, an automatic payment solution; Zaptec Portal for monitoring, balancing, and optimizing the load between the various charging stations; and Zaptec Sense for automatically adjusting the charging speed in the buildings. The company was founded in 2012 and is based in Stavanger, Norway.
Oslo Børs Benchmark Index_GI ended the session with ZAPTEC jumping 14.27% to €20.26 on Wednesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI slid 0.2% to €1,297.01, following the last session’s downward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, ZAPTEC has a trailing twelve months EPS of kr0.02.
PE Ratio
ZAPTEC has a trailing twelve months price to earnings ratio of 1013. Meaning, the purchaser of the share is investing kr1013 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.15%.
Yearly Top and Bottom Value
ZAPTEC’s stock is valued at kr20.26 at 21:40 EST, way under its 52-week high of kr43.78 and way higher than its 52-week low of kr15.66.
Sales Growth
ZAPTEC’s sales growth for the current quarter is 54.2%.
Volume
Today’s last reported volume for ZAPTEC is 1971540 which is 294.76% above its average volume of 499423.
More news about ZAPTEC.
3. SYNERGIE (SDG.PA)
11.29% Price Change
Synergie SE provides human resources management and development services for companies and institutions in France, Belgium, Other Northern and Eastern Europe, Italy, Spain, Portugal, Canada, and Australia. It offers temporary work, recruitment, out-placement, social engineering, consultancy, and training services. The company serves various specialized sectors and industries, such as renewable energy, transport and logistics, construction and public works, healthcare, agri-food, and tertiary sectors. Synergie SE was founded in 1969 and is headquartered in Paris, France.
CAC 40 ended the session with SYNERGIE jumping 11.29% to €34.50 on Wednesday while CAC 40 jumped 0.12% to €7,583.43.
Earnings Per Share
As for profitability, SYNERGIE has a trailing twelve months EPS of €3.51.
PE Ratio
SYNERGIE has a trailing twelve months price to earnings ratio of 9.83. Meaning, the purchaser of the share is investing €9.83 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.82%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.6%, now sitting on 3B for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 29, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 2.61%.
Volatility
SYNERGIE’s last week, last month’s, and last quarter’s current intraday variation average was 0.33%, 0.04%, and 1.17%.
SYNERGIE’s highest amplitude of average volatility was 1.63% (last week), 0.82% (last month), and 1.17% (last quarter).
More news about SYNERGIE.
4. NEW SOURCES ENERGY (NSE.AS)
10% Price Change
New Sources Energy N.V. develops, operates, exploits, and invests in projects that generates electricity using renewable energy sources. The company was formerly known as Management Share NV and changed its name to New Sources Energy N.V. in July 2011. New Sources Energy N.V. is headquartered in Amersfoort, the Netherlands.
AEX-Index ended the session with NEW SOURCES ENERGY rising 10% to €0.04 on Wednesday while AEX-Index jumped 0.15% to €793.69.
Volume
Today’s last reported volume for NEW SOURCES ENERGY is 40000 which is 6.31% below its average volume of 42696.
More news about NEW SOURCES ENERGY.
5. NORTHERN OCEAN LTD (NOL.OL)
8.89% Price Change
Northern Ocean Ltd., a drilling contractor, provides offshore contract drilling services for the oil and gas industry worldwide. The company was incorporated in 2017 and is based in Hamilton, Bermuda.
Oslo Børs Benchmark Index_GI ended the session with NORTHERN OCEAN LTD jumping 8.89% to €10.78 on Wednesday while Oslo Børs Benchmark Index_GI dropped 0.2% to €1,297.01.
Earnings Per Share
As for profitability, NORTHERN OCEAN LTD has a trailing twelve months EPS of kr-4.42.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.86%.
More news about NORTHERN OCEAN LTD.
6. DBV TECHNOLOGIES (DBV.PA)
8.48% Price Change
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
CAC 40 ended the session with DBV TECHNOLOGIES jumping 8.48% to €1.89 on Wednesday, after four sequential sessions in a row of gains. CAC 40 jumped 0.12% to €7,583.43, following the last session’s upward trend on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, DBV TECHNOLOGIES has a trailing twelve months EPS of €-1.01.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -56.61%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DBV TECHNOLOGIES’s stock is considered to be oversold (<=20).
More news about DBV TECHNOLOGIES.
7. MAISONS DU MONDE (MDM.PA)
8.08% Price Change
Maisons du Monde S.A., through its subsidiaries, provides home and living room related products in France and internationally. The company's decorative products include bed linen products, carpets, candles, pillows and cushions, clocks, tableware, lamps, kitchen utensils, mirrors and frames, vases, storage units, curtains and net curtains, and bath products. It also provides furniture, such as sofas, chairs, beds, mattresses and bedframes, floor lamps, tables, and junior furniture; and tables and storage units comprising bookshelves, wardrobes, and cupboards, as well as outdoor furniture. In addition, the company offers warehouse logistics and order preparation services, as well as container transport services between harbor and warehouses. It provides its products under the Maisons du Monde brand. The company was founded in 1996 and is based in Vertou, France.
CAC 40 ended the session with MAISONS DU MONDE rising 8.08% to €5.55 on Wednesday, following the last session’s upward trend. CAC 40 jumped 0.12% to €7,583.43, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, MAISONS DU MONDE has a trailing twelve months EPS of €0.62.
PE Ratio
MAISONS DU MONDE has a trailing twelve months price to earnings ratio of 8.95. Meaning, the purchaser of the share is investing €8.95 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.3%.
Volume
Today’s last reported volume for MAISONS DU MONDE is 71742 which is 11.13% below its average volume of 80735.
More news about MAISONS DU MONDE.
8. ADOCIA (ADOC.PA)
7.87% Price Change
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
CAC 40 ended the session with ADOCIA rising 7.87% to €10.14 on Wednesday, following the last session’s upward trend. CAC 40 jumped 0.12% to €7,583.43, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, ADOCIA has a trailing twelve months EPS of €-2.5.
Volume
Today’s last reported volume for ADOCIA is 412145 which is 130.78% above its average volume of 178584.
Volatility
ADOCIA’s last week, last month’s, and last quarter’s current intraday variation average was 4.21%, 0.34%, and 4.45%.
ADOCIA’s highest amplitude of average volatility was 6.26% (last week), 3.51% (last month), and 4.45% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ADOCIA’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
ADOCIA’s stock is valued at €10.14 at 21:40 EST, way below its 52-week high of €16.16 and way above its 52-week low of €2.74.
More news about ADOCIA.
9. INNATE PHARMA (IPH.PA)
7.72% Price Change
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
CAC 40 ended the session with INNATE PHARMA jumping 7.72% to €2.65 on Wednesday, following the last session’s upward trend. CAC 40 jumped 0.12% to €7,583.43, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, INNATE PHARMA has a trailing twelve months EPS of €-0.79.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -71.91%.
Yearly Top and Bottom Value
INNATE PHARMA’s stock is valued at €2.65 at 21:40 EST, way under its 52-week high of €3.80 and way higher than its 52-week low of €1.99.
Revenue Growth
Year-on-year quarterly revenue growth declined by 11.8%, now sitting on 52.28M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, INNATE PHARMA’s stock is considered to be oversold (<=20).
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 4.64%.
More news about INNATE PHARMA.
10. ALAN ALLMAN (AAA.PA)
6.45% Price Change
Alan Allman Associates, together with its subsidiaries, engages in the provision of consulting services in Canada, France, Belgium, Luxembourg, Switzerland, and Singapore. The company offers technology consulting in the areas, including cybersecurity, cloud, data management, digitalization of tools and processes, etc.; strategy and management consulting comprising risk management, commercial intelligence, market finance, process management, change management, etc.; and industrial transformation consulting, such as purchasing and supply chain issues, relocation, cost reduction, project management, materials, process consulting, etc. The company was incorporated in 1954 and is based in Issy-les-Moulineaux, France.
CAC 40 ended the session with ALAN ALLMAN jumping 6.45% to €9.90 on Wednesday while CAC 40 jumped 0.12% to €7,583.43.
Earnings Per Share
As for profitability, ALAN ALLMAN has a trailing twelve months EPS of €0.19.
PE Ratio
ALAN ALLMAN has a trailing twelve months price to earnings ratio of 52.11. Meaning, the purchaser of the share is investing €52.11 for every euro of annual earnings.
More news about ALAN ALLMAN.
Losers Today
1. ARGENX SE (ARGX.BR)
-23.63% Price Change
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
BEL 20 ended the session with ARGENX SE sliding 23.63% to €317.00 on Wednesday while BEL 20 dropped 2.4% to €3,652.82.
Earnings Per Share
As for profitability, ARGENX SE has a trailing twelve months EPS of €-3.78.
Volume
Today’s last reported volume for ARGENX SE is 214763 which is 261.91% above its average volume of 59340.
Volatility
ARGENX SE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.66%, a negative 0.42%, and a positive 1.41%.
ARGENX SE’s highest amplitude of average volatility was 0.66% (last week), 1.51% (last month), and 1.41% (last quarter).
More news about ARGENX SE.
2. CFI (CFI.PA)
-13.04% Price Change
CFI-Compagnie Foncière Internationale, a real estate investment company, engages in leasing land and other property assets. The company was formerly known as Didot-Bottin and changed its name on December 9, 2008. As of December 31, 2009, its real estate portfolio comprised 12 assets located in France. CFI-Compagnie Foncière Internationale was founded in 1796 and is based in Paris, France.
CAC 40 ended the session with CFI dropping 13.04% to €0.60 on Wednesday while CAC 40 jumped 0.12% to €7,583.43.
Earnings Per Share
As for profitability, CFI has a trailing twelve months EPS of €-0.2.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -866.67%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CFI’s stock is considered to be oversold (<=20).
More news about CFI.
3. MCPHY ENERGY (MCPHY.PA)
-12.03% Price Change
McPhy Energy S.A. provides hydrogen production and distribution equipment for hydrogen energy, hydrogen mobility, and industrial hydrogen markets. The company offers alkaline electrolyzers; hydrogen storage and transportation solutions; and fuel cell systems. It also develops hydrogen stations; and provides integrated hydrogen solutions. The company operates in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. McPhy Energy S.A. was incorporated in 2007 and is headquartered in Grenoble, France.
CAC 40 ended the session with MCPHY ENERGY dropping 12.03% to €3.29 on Wednesday, after four sequential sessions in a row of gains. CAC 40 rose 0.12% to €7,583.43, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, MCPHY ENERGY has a trailing twelve months EPS of €-1.51.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.8%.
Volatility
MCPHY ENERGY’s last week, last month’s, and last quarter’s current intraday variation average was a positive 4.46%, a negative 0.12%, and a positive 2.84%.
MCPHY ENERGY’s highest amplitude of average volatility was 4.46% (last week), 2.73% (last month), and 2.84% (last quarter).
More news about MCPHY ENERGY.
4. ADC SIIC (ALDV.PA)
-10.71% Price Change
Alliance Developpement Capital SIIC (ADC SIIC) is a publicly owned real estate investment firm. The firm specializes in owning and managing residential real estate properties. It primarily invests in properties in Paris and its suburbs. The firm was formerly known as AD Capital SA. Alliance Developpement Capital is based in Saint-Josse-Ten-Noode, Belgium.
CAC 40 ended the session with ADC SIIC sliding 10.71% to €0.06 on Wednesday, after five sequential sessions in a row of losses. CAC 40 rose 0.12% to €7,583.43, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.45%.
More news about ADC SIIC.
5. MOTA ENGIL (EGL.LS)
-9.29% Price Change
Mota-Engil, SGPS, S.A. provides construction and infrastructure management services in Europe, Africa, and Latin America. Its construction and infrastructure projects, including airports, railways, hydraulic, ports, roads, and urban facilities; and agricultural and industrial, public building, office and commerce, housing, and silo and chimney projects, as well as provides buildings rehabilitation services. The company also collects, treats, recovers, and disposes urban waste, and hazardous and non-hazardous; explores and prospects mineral resources; and generates and distributes electricity through hydro and bioenergy sources. In addition, it designs and constructs social housing; promotes and manages technological parks; develops real estate; and manages financial holdings. Further, the company provides terminal exploration, inspection, business administration, commercial, sea transport, sustainable mobility, logistics, technical consultancy, engineering and architecture, tourism, road signs, and restaurant services; designs, constructs, manages, and exploits parking; rents construction equipment; manufactures and trades in clay materials; and operates industrial slaughterhouse. Additionally, it is involved in construction and maintenance of amusement park; construction and public works; construction, renovation, and repair of residential buildings; exploring, extracting, drilling, pumping, supplying, and transporting of oil, gas, petroleum, and other related products; and stainless steel works, maintenance and operation of facilities, insurance mediation, and finance and consulting activities. The company was founded in 1946 and is headquartered in Porto, Portugal.
PSI ended the session with MOTA ENGIL sliding 9.29% to €3.71 on Wednesday, after three successive sessions in a row of losses. PSI slid 0.32% to €6,344.54, after three successive sessions in a row of losses, on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, MOTA ENGIL has a trailing twelve months EPS of €0.2.
PE Ratio
MOTA ENGIL has a trailing twelve months price to earnings ratio of 18.55. Meaning, the purchaser of the share is investing €18.55 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.88%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MOTA ENGIL’s stock is considered to be overbought (>=80).
Volatility
MOTA ENGIL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.79%, a positive 1.14%, and a positive 2.13%.
MOTA ENGIL’s highest amplitude of average volatility was 1.27% (last week), 1.91% (last month), and 2.13% (last quarter).
Yearly Top and Bottom Value
MOTA ENGIL’s stock is valued at €3.71 at 21:40 EST, way above its 52-week high of €2.51.
More news about MOTA ENGIL.
6. PCI BIOTECH HOLD (PCIB.OL)
-8.45% Price Change
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD falling 8.45% to €2.01 on Wednesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI slid 0.2% to €1,297.01, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.
More news about PCI BIOTECH HOLD.
7. OCEANTEAM (OTS.OL)
-8.27% Price Change
Oceanteam ASA operates as a subsea and offshore services company in Europe. It provides equipment for offshore cable laying, umbilical installations, and on- and offshore storage and transport. The company also rents turntables, tensioners, reels, demountable turntable systems, and other cable handling and storage equipment, as well as offers cable and umbilical storage, and handling solutions. It serves renewable energy, and oil and gas industries. The company was formerly known as Oceanteam Shipping ASA and changed its name to Oceanteam ASA in December 2015. Oceanteam ASA was incorporated in 2005 and is headquartered in Bærum, Norway.
Oslo Børs Benchmark Index_GI ended the session with OCEANTEAM falling 8.27% to €1.28 on Wednesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI slid 0.2% to €1,297.01, following the last session’s downward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, OCEANTEAM has a trailing twelve months EPS of kr-0.31.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.62%.
Moving Average
OCEANTEAM’s worth is way below its 50-day moving average of kr1.43 and way below its 200-day moving average of kr1.55.
More news about OCEANTEAM.
8. EQVA (EQVA.OL)
-5.85% Price Change
Eqva ASA, a knowledge-based maritime company, primarily engages in the shipbuilding business worldwide. It operates in two segments, Shipbuilding Technology and Other. The company provides newbuilding, rebuilding, and service assignments on vessels for offshore oil production, renewable energy production, fishing, and fish farming for ship owners. It delivers technology for customers within the seafood, energy, and transport sectors. The company was formerly known as Havyard Group ASA and changed its name to Eqva ASA in November 2022. Eqva ASA was founded in 1999 and is headquartered in Fosnavåg, Norway.
Oslo Børs Benchmark Index_GI ended the session with EQVA dropping 5.85% to €3.06 on Wednesday while Oslo Børs Benchmark Index_GI dropped 0.2% to €1,297.01.
Earnings Per Share
As for profitability, EQVA has a trailing twelve months EPS of kr-0.32.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.45%.
Yearly Top and Bottom Value
EQVA’s stock is valued at kr3.06 at 21:40 EST, way under its 52-week high of kr4.00 and way above its 52-week low of kr2.56.
Volume
Today’s last reported volume for EQVA is 32828 which is 18.43% below its average volume of 40248.
Revenue Growth
Year-on-year quarterly revenue growth grew by 209.8%, now sitting on 594.65M for the twelve trailing months.
More news about EQVA.
9. SOLSTAD OFFSHORE (SOFF.OL)
-5.75% Price Change
Solstad Offshore ASA operates offshore service vessels and maritime services to offshore energy industry. It owns and operates platform supply vessel, anchor handling tug support vessel, and construction service vessels. The company offers subsea construction and renewable energy services, such as geotechnical work, walk to work services, grouting, SURF operations, cable laying and repair, trenching and burial, ROV support, installation of subsea equipment, survey work, IMR operations, node seismic operations, and diving and topside maintenance work. It operates a fleet of 27 construction service vessels, 20 anchor handling tug support vessels, and 39 platform supply vessels. The company was founded in 1964 and is headquartered in Skudeneshavn, Norway.
Oslo Børs Benchmark Index_GI ended the session with SOLSTAD OFFSHORE dropping 5.75% to €39.02 on Wednesday while Oslo Børs Benchmark Index_GI fell 0.2% to €1,297.01.
Earnings Per Share
As for profitability, SOLSTAD OFFSHORE has a trailing twelve months EPS of kr0.6.
PE Ratio
SOLSTAD OFFSHORE has a trailing twelve months price to earnings ratio of 65.03. Meaning, the purchaser of the share is investing kr65.03 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.44%.
Yearly Top and Bottom Value
SOLSTAD OFFSHORE’s stock is valued at kr39.02 at 21:40 EST, way under its 52-week high of kr52.00 and way higher than its 52-week low of kr16.88.
Volatility
SOLSTAD OFFSHORE’s last week, last month’s, and last quarter’s current intraday variation average was 6.22%, 1.83%, and 4.01%.
SOLSTAD OFFSHORE’s highest amplitude of average volatility was 6.22% (last week), 4.33% (last month), and 4.01% (last quarter).
Volume
Today’s last reported volume for SOLSTAD OFFSHORE is 1012640 which is 32.17% below its average volume of 1492960.
More news about SOLSTAD OFFSHORE.
10. PORCELEYNE FLES (PORF.AS)
-5.38% Price Change
B.V. Delftsch Aardewerkfabriek "De Porceleyne Fles Anno 1653" produces and sells Delft Blue decorative pottery and modern pottery products in the Netherlands. The company is involved in the purchasing, operation, management, and leasing of real estate properties. B.V. Delftsch Aardewerkfabriek "De Porceleyne Fles Anno 1653" was founded in 1653 and is based in Delft, the Netherlands.
AEX-Index ended the session with PORCELEYNE FLES dropping 5.38% to €12.30 on Wednesday while AEX-Index jumped 0.15% to €793.69.
Earnings Per Share
As for profitability, PORCELEYNE FLES has a trailing twelve months EPS of €0.4.
PE Ratio
PORCELEYNE FLES has a trailing twelve months price to earnings ratio of 30.75. Meaning, the purchaser of the share is investing €30.75 for every euro of annual earnings.
Volume
Today’s last reported volume for PORCELEYNE FLES is 5 which is 93.9% below its average volume of 82.
More news about PORCELEYNE FLES.
Stay up to date with our winners and losers daily report
